Share on StockTwits

Equities researchers at Canaccord Genuity decreased their price objective on shares of EnteroMedics (NASDAQ:ETRM) from $6.00 to $4.00 in a research report issued on Thursday, AR Network reports. Canaccord Genuity’s target price would suggest a potential upside of 112.77% from the stock’s previous close.

Separately, analysts at Northland Securities reiterated a “buy” rating on shares of EnteroMedics in a research note on Monday, April 21st. Three research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $4.60.

Shares of EnteroMedics (NASDAQ:ETRM) remained flat at $1.88 during during mid-day trading trading on Thursday. 828,920 shares of the company’s stock traded hands. EnteroMedics has a 52 week low of $0.85 and a 52 week high of $2.66. The stock’s 50-day moving average is $1.85 and its 200-day moving average is $1.90. The company’s market cap is $125.1 million.

EnteroMedics (NASDAQ:ETRM) last announced its earnings results on Wednesday, April 30th. The company reported ($0.10) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.10). During the same quarter last year, the company posted ($0.14) earnings per share. On average, analysts predict that EnteroMedics will post $-0.37 earnings per share for the current fiscal year.

EnteroMedics Inc (NASDAQ:ETRM) is a development- stage medical device company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.